In this study, we demonstrated that chidamide exerted antileukemia activity in AML cells and stem/progenitor cells and increased sensitivity to adriamycin in vitro and in vivo by inhibiting EZH2 through Smo/Gli-1 pathway. Here, EZH2 is linked to acute myeloid leukemia.